Home » Archive

News

Marketwire, News, Syndication »

Ardea Biosciences Announces Expiration of HSR Waiting Period in Connection With Proposed Merger

Posted by Mary Canady June 5th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jun 5, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) (“Ardea”), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced the expiration of …

More...

Diagnostics, News, Syndication, Xconomy »

ASCO Wrap-Up: A Summary of This Week’s Cancer R&D Headlines

Posted by sandiegobiotech June 5th, 2012 .
No Comments

There’s so much going on in the world of cancer drug R&D that it’s hard to keep up with all the news about drugs that are changing the standards of care. And quite a few of those standards are…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Building Bridges in a New Global Health Landscape

Posted by sandiegobiotech June 4th, 2012 .
No Comments

[Editor's note: This article is adapted from a speech given at PATH’s annual Breakfast for Global Health on May 22, 2012.] Today I begin a new chapter in my life as president and CEO of the global…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Medistem Achieves Important ERC Stem Cell Clinical Trial Milestone

Posted by Mary Canady June 4th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Jun 4, 2012) – Medistem Inc. (PINKSHEETS: MEDS) announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DE…

More...

News, Syndication, Xconomy »

Why Would a Biotech Company Go the Trouble of Changing Its Name?

Posted by sandiegobiotech June 4th, 2012 .
No Comments

[Updated 1:26 pm PT with survey results] If you’re trying to figure out what the heck a certain biotech company does, the last place to look is usually the company name. Names often don’t mean much,…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early

Posted by sandiegobiotech June 3rd, 2012 .
No Comments

One of the more anticipated clinical trials at this year’s American Society of Clinical Oncology (ASCO) meeting was for Johnson & Johnson’s abiraterone (Zytiga) in prostate cancer patients. This…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

New San Diego VC Firm Emerges as ‘The Moneyball of Venture Capital’

Posted by sandiegobiotech June 1st, 2012 .
No Comments

[Corrected 6/5/12, 10:05 pm. See below.] Here’s some big news for San Diego’s innovation economy: There’s a new venture capital firm in town—and its investment methodology represents a fundamentally…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Quidel to Present at Upcoming Conferences

Posted by Mary Canady May 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 31, 2012) – Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today that it will present at the following upcoming conferences:

More...

Marketwire, News, Syndication »

Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers

Posted by Mary Canady May 31st, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 31, 2012) – Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion d…

More...

Drug Development, News, Syndication, Xconomy »

SD Biotech Roundup: Wireless Sensor Prize, Zogenix, Sangart, & More

Posted by sandiegobiotech May 31st, 2012 .
No Comments

The X Prize Foundation’s Peter Diamandis came to San Diego to announce the formation of a new incentive prize competition, while a variety of companies disclosed new funding deals. It’s all part of…

[[Click headline to continue reading.]]

More...